Less than 1 min.Read

Curi Bio: Raises $6M in Series A Financing

March 21, 2021

Curi Bio Inc., a Seattle, WA-based developer of human stem cell-based platforms for drug discovery, raised $6m in Series A financing round
The round, also led by Dynamk Capital, expected to close with additional investors by the end of Q2 2021
With this financing round, Dr. Gustavo Mahler, Managing Partner at Dynamk Capital, joined Curi Bio’s as a new board member
The company also intends to use the funds to scale its existing business and accelerate the development of new innovative human stem cell platforms
Curi Bio also provides a preclinical discovery platform that combines human stem cells, systems, and data to accelerate the discovery of new medicines
The Curi Engine is a bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and A.I./M.L.-enabled phenotypic screening data